A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

Item
http://www.wikidata.org/entity/Q33375169
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesBendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyThe role of bendamustine in the treatment of indolent non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaDetermination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug MonitoringDevelopment and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.Bendamustine in the treatment of chronic lymphocytic leukemia.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
P2860

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

Item
http://www.wikidata.org/entity/Q33375169
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase I study of bendamustin ...... n patients with solid tumours.
@ast
A phase I study of bendamustin ...... n patients with solid tumours.
@en
type
label
A phase I study of bendamustin ...... n patients with solid tumours.
@ast
A phase I study of bendamustin ...... n patients with solid tumours.
@en
prefLabel
A phase I study of bendamustin ...... n patients with solid tumours.
@ast
A phase I study of bendamustin ...... n patients with solid tumours.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
A phase I study of bendamustin ...... n patients with solid tumours.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932